Demand for Rare Hemophilia Factors Is Slated to Increase A Valuation of US$ 520 Million by 2033

According to the latest published industry report by Fact.MR, a market research and competitive intelligence provider, the global rare hemophilia factors market is valued at US$ 290 million in 2023 and is forecasted to expand at 6% CAGR through 2033.

A major issue for the healthcare industry is the growing prevalence of uncommon illnesses among people worldwide. One of the rarest bleeding conditions, hemophilia, is characterized by insufficient clotting factors in the blood. Because the hemophilia gene is defective, hemophilia patients typically bleed unnaturally and for a longer period than healthy individuals. Around 70% of hemophilia cases are hereditary and are typically brought on by gene mutation.

Hemophilia patients can lead healthy lives if they receive proper and successful therapy. The patient receives an injection of the missing clotting factors to stop the abnormal bleeding. The population's growing knowledge of such rare diseases and government involvement in their prevention and control are elements driving market value growth. The overall demand for rare hemophilia factors is predicted to increase during the forecast period due to the rapidly growing global hemophilia patient pool and improvements in hemophilia treatment methods.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:- https://www.factmr.com/connectus/sample?flag=S&rep_id=7801?PJ

One of the major trends for rare hemophilia that is anticipated to have a beneficial impact on market expansion over the coming years is the advent of gene therapy. Delivering stable insertion and expression of a gene, whose absence causes hemophilia A or B, is the goal of gene therapy for hemophilia.

The market is also expanding due to many other variables, such as the rising adoption and approval of innovative treatment modalities and an increase in the number of government programs.

𝐒𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:

• Amgen Inc.
• BioMarin
• Bio Products Laboratory Ltd.
• Biogen Inc.
• CSL Behring
• Baxter International Inc.
• Bayer AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Takeda Pharmaceutical Co. Ltd.
• Alexion Pharmaceuticals, Inc.
• Shire plc
• ICON plc

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7801?PJ

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝

• By Type :

• Factor I
• Factor II
• Factor V
• Factor VII
• Factor X
• Factor XI
• Factor XIII

• By Application :

• Fresh Frozen Plasma
• Factor Concentrates
• Cryoprecipitate

• By Region :

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Takeaways from Market Study

• Market in Canada is forecasted to expand at a CAGR of 5.3% over the forecast period (2022-2032).
• The global rare hemophilia factors market is predicted to reach US$ 520 million by 2032.
• Market in Japan is anticipated to progress at a CAGR of 5.7% through 2032.
• Demand for factor concentrates is estimated to rise at a CAGR of 5.8% from 2022 to 2032.

"Patients and healthcare professionals are becoming more knowledgeable of rare hemophilia coagulation illnesses due to government activities and regulations, which has boosted the rate of diagnosis and therapy for this condition," says a Fact.MR analyst

Winning Strategy

Top market players are focused on introducing innovative therapies for hemophilia that are both effective and affordable.

For instance,

• In 2022, with the introduction of Adynovate, Takeda Pharmaceutical Co Ltd. announced the extension of its portfolio for rare diseases in India. Adynovate is a cutting-edge prolonged half-life recombinant Factor VIII (rFVIII) therapy for hemophilia A patients that make use of proven technology

𝐅𝐮𝐥𝐥 𝐀𝐜𝐜𝐞𝐬𝐬 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭: https://www.factmr.com/checkout/7801

More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global rare hemophilia factors market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2032.

The study divulges essential insights on the market on the basis of type (factor I, factor II, factor V, factor VII, factor X, factor XI, factor XIII) and application (fresh frozen plasma, factor concentrates, cryoprecipitate, others), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).

𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐛𝐲 𝐅𝐚𝐜𝐭.𝐌𝐑 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
https://www.prnewswire.com/news-releases/anesthesia-monitoring-devices-market-to-exceed-us-3-4-billion-by-2027-amid-rising-prevalence-of-degenerative-and-chronic-illnesses-301659609.html

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.